COMMUNIQUÉS West-GlobeNewswire

OSE Immunotherapeutics annonce la présentation des résultats de l'étude de Phase 2 TEDOVA de Tedopi® dans le cancer de l’ovaire au Congrès 2026 de l’ASCO
23/04/2026
Nantes, France, 23 avril 2026 – 7h30 CEST – OSE Immunotherapeutics SA (ISIN : FR0012127173 ; Mnemo : OSE) , une société de biotechnologie au stade clinique développant des thérapies first-in-class en immuno-oncologie et [...]
Press Release: Q1 2026: double-digit sales and business EPS growth
23/04/2026
Q1 2026: double-digit sales and business EPS growth Paris, April 23, 2026 Q1 sales growth of 13.6% at CER 1 and business earnings per share (EPS) 2 of €1.88 Pharma launches sales increased by 49.6%, reaching €1.2 [...]
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth of +6% at constant exchange rates in the first quarter of 2026; -5% in CHF due to the significant appreciation of the Swiss franc
23/04/2026
Group sales were +6% at constant exchange rates (CER) 1 , -5% when reported in CHF and +9% in USD 2 , in the first three months, driven by high demand for our innovative medicines and diagnostics. Pharmaceuticals [...]
Communiqué de presse : T1 2026 : croissance à deux chiffres du chiffre d’affaires et du BNPA
23/04/2026
T1 2026 : croissance à deux chiffres du chiffre d’affaires et du BNPA Paris, le 23 avril 2026 Ventes du T1 en progression de 13,6 % à TCC 1 et BNPA 2 des activités de 1,88 euro Les ventes des nouveaux lancements Pharma [...]
Une découverte susceptible de valoir un prix Nobel par les scientifiques de VectorBuilder révèle les mécanismes fondamentaux du développement
23/04/2026
CHICAGO, 23 avr. 2026 (GLOBE NEWSWIRE) -- L’une des questions les plus fondamentales de la biologie est de comprendre comment un seul œuf fécondé produit la diversité des types cellulaires constituant le corps — des [...]
Ipsen enregistre une forte croissance de ses ventes au premier trimestre 2026 et confirme ses objectifs annuels
23/04/2026
Croissance du chiffre d’affaires total de 22,6 % à taux de change constant 1 , ou 17,0 % en données publiées, portée par les trois aires thérapeutiques, avec une accélération de la dynamique du portefeuille hors [...]
Vivoryon Therapeutics N.V. Reports Full Year 2025 Financial Results and Provides Business Update
23/04/2026
Vivoryon Therapeutics N.V. Reports Full Year 2025 Financial Results and Provides Business Update Compelling kidney function data and meta-analysis from two Phase 2 studies with varoglutamstat presented at ERA 2025, ASN [...]
Addex Spin-Out Company Neurosterix on Track to Complete Phase 1 Clinical Study of NTX-253 for Schizophrenia in Q2 2026
23/04/2026
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, April 23, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel [...]
Ipsen delivers strong sales in the first quarter of 2026 and confirms its full-year guidance
23/04/2026
Total sales growth of 22.6% at CER 1 or 17.0% as reported, driven by all three therapeutic areas, with accelerating portfolio momentum outside Somatuline ® , growing by 27.5% at CER Strong pipeline momentum with three [...]
Altimmune Announces Pricing of $225 Million Oversubscribed Public Offering of Securities
23/04/2026
GAITHERSBURG, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced the pricing [...]
New funding opportunities pave the way for better diagnostics and treatment as well as for engineering efficient biosolutions and replacing critical and scarce resources
23/04/2026
COPENHAGEN, Denmark, April 23, 2026 (GLOBE NEWSWIRE) -- The Novo Nordisk Foundation Challenge Programme supports development of new knowledge to help tackle major societal challenges within human and planetary health. [...]
Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)
23/04/2026
CHICAGO, April 22, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) today announced that it has entered into a co-development agreement with Adbiotech Co., Ltd. (KOSDAQ: 179530), a Korea-based biotechnology company [...]
Altimmune Announces Proposed Underwritten Public Offering of Securities
22/04/2026
GAITHERSBURG, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced it has [...]
OraSure to Announce First Quarter 2026 Financial Results and Host Earnings Call on May 6th
22/04/2026
BETHLEHEM, Pa., April 22, 2026 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering first quarter 2026 financial results and certain business [...]
Dentsply Sirona to Host First Quarter 2026 Conference Call on May 5
22/04/2026
CHARLOTTE, N.C., April 22, 2026 (GLOBE NEWSWIRE) -- DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the "Company") (Nasdaq: XRAY) today announced that the Company will host an investor conference call and live webcast on [...]
Silo Pharma Announces Strategic Business Expansion into Multi-Billion Dollar AI Agent Market with Acquisition of Managed AI Agent Platform, Qwikagents
22/04/2026
Launch of Dedicated AI Subsidiary Positions Company for New Revenue Streams While Advancing PTSD Program Toward Phase 1 SARASOTA, FL, April 22, 2026 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the [...]
Supernus Pharmaceuticals to Announce First Quarter 2026 Financial Results and Host Conference Call on May 5, 2026
22/04/2026
ROCKVILLE, Md., April 22, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous [...]
RxSight, Inc. to Report First Quarter 2026 Financial Results on May 6
22/04/2026
ALISO VIEJO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., today announced that it will report financial results for the first quarter after the market close on Wednesday, May 6, 2026. The [...]
Dupixent® (dupilumab) Approved in the U.S. as the First Biologic Medicine for Young Children with Uncontrolled Chronic Spontaneous Urticaria (CSU)
22/04/2026
Approval for children aged 2 to 11 years with CSU who remain symptomatic despite H1 antihistamine treatment based primarily on data from the LIBERTY-CUPID clinical trial program CSU is a chronic skin disease that causes [...]

Pages